SM-102: Ionizable Lipid for mRNA Vaccine Lipid Nanoparticle Delivery

Executive Summary: SM-102 is a synthetic ionizable lipid routinely used in lipid nanoparticle (LNP) systems to encapsulate and deliver mRNA molecules into cells with high efficiency (Wang et al., 2022). Its molecular weight is 710.18 g/mol, and it shows high solubility in ethanol (≥175.8 mg/mL) but is insoluble in DMSO and water (APExBIO). SM-102 is validated for ≥98.00% purity by mass spectrometry and NMR and is a key component in mRNA vaccine delivery systems, supporting efficient cellular uptake and endosomal escape (Wang et al., 2022). Its performance has been benchmarked against other ionizable lipids using both in vivo models and computational predictions. Proper storage at −20°C is required for stability, with no recommendation for long-term solution storage.

Biological Rationale

Lipid nanoparticles (LNPs) have emerged as the leading non-viral vehicles for mRNA delivery. They protect mRNA from enzymatic degradation and facilitate cellular uptake. The rapid development and high efficacy of LNP-based mRNA vaccines for COVID-19 validate this technology (Wang et al., 2022). SM-102, as an ionizable lipid, provides a cationic environment at acidic pH, aiding mRNA complexation and endosomal escape. LNPs for mRNA delivery typically consist of four components: cholesterol, DSPC, PEG-lipid, and an ionizable lipid such as SM-102 (Wang et al., 2022).

Mechanism of Action of SM-102

SM-102 operates as an ionizable amino lipid. At neutral pH, it is mainly uncharged, minimizing toxicity. Under acidic conditions, such as those found in endosomes, SM-102 becomes protonated, acquiring a positive charge. This enables electrostatic interaction with the mRNA and destabilizes endosomal membranes, facilitating mRNA release into the cytoplasm (Wang et al., 2022).

SM-102’s molecular structure—heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate—features a hydrophobic tail and a tertiary amine headgroup. This amphiphilic design is critical for nanoparticle self-assembly and endosomal escape. Computational and experimental studies confirm SM-102’s role in LNP aggregation and mRNA encapsulation efficiency (Wang et al., 2022).

Evidence & Benchmarks

• SM-102 achieves high mRNA encapsulation efficiency in LNP formulations, exceeding 90% under standard conditions (Wang et al., DOI).
• LNPs formulated with SM-102 demonstrate robust in vivo delivery and protein expression in murine models (Wang et al., DOI).
• Machine learning models predict and validate SM-102 as an effective ionizable lipid for mRNA vaccines but slightly less efficient than MC3 under certain N/P ratios (Wang et al., DOI).
• SM-102’s purity (≥98.00%) is confirmed by mass spectrometry and NMR, ensuring batch-to-batch reproducibility (APExBIO).
• Stability is highest when SM-102 is stored at −20°C or lower, with limited solution stability (APExBIO).

This article extends insights found in SM-102 in Lipid Nanoparticles: Mechanisms, Evidence & mRNA Delivery by providing more granular evidence on purity, storage, and comparative efficiency.

For protocol integration and troubleshooting, see SM-102 Lipid Nanoparticles: Optimizing mRNA Delivery Workflows; this article updates with the latest computational benchmarks and storage conditions.

For a predictive analytics perspective, SM-102 in Lipid Nanoparticles: Integrating Predictive Modeling focuses on machine learning, while this article details wet-lab and purity validation.

Applications, Limits & Misconceptions

• Applications: SM-102 is used in lipid nanoparticle formulations for mRNA vaccine development, including preclinical and clinical research for infectious diseases and therapeutics (Wang et al., 2022).
• It is suitable for rapid prototyping and screening of mRNA vaccine candidates in vitro and in vivo.
• SM-102 is widely referenced in computational modeling for LNP optimization (Wang et al., 2022).

Common Pitfalls or Misconceptions

• SM-102 is not soluble in DMSO or water; only use ethanol as a solvent at ≥175.8 mg/mL (APExBIO).
• Long-term storage of SM-102 solutions is not recommended; only store as a solid at –20°C or below (APExBIO).
• SM-102, while potent, may show slightly lower delivery efficiency compared to MC3 in certain mouse models at specific N/P ratios (Wang et al., 2022).
• It is not approved for direct clinical use; intended for research only.
• Its performance can be highly context-dependent (e.g., cell type, mRNA length, LNP composition).

Workflow Integration & Parameters

For optimal use, dissolve SM-102 in ethanol at or above 175.8 mg/mL and store aliquots at −20°C. Avoid repeated freeze-thaw cycles. LNP formulations typically use SM-102 in combination with cholesterol, DSPC, and PEG-lipid. The N/P (nitrogen to phosphate) ratio is a key parameter, commonly ranging from 6:1 to 12:1 in mouse models (Wang et al., 2022).

Batch-to-batch consistency is supported by ≥98.00% purity, validated by mass spectrometry and NMR (see the C1042 kit from APExBIO). Shipping is performed with blue ice for small molecules and dry ice for nucleotides. For scenario-driven protocols, refer to SM-102 (SKU C1042): Reliable Ionizable Lipid for Advanced LNPs, which this article updates with storage and purity specifics.

Conclusion & Outlook

SM-102 is a validated ionizable lipid excipient for mRNA vaccine LNPs. Its well-characterized solubility, purity, and storage parameters enable robust and reproducible mRNA delivery in experimental systems. While alternative lipids may outperform SM-102 in specific settings, it remains a reference standard in both empirical and computational benchmarking. Continuing advances in predictive modeling and formulation science will further refine the role of SM-102 and related lipids in next-generation mRNA therapeutics (Wang et al., 2022).